Charleston Laboratories, Inc. (CL) is an innovative, specialty pharmaceutical company in the narcotic analgesic market sector that was founded late 2007. CL has identified a novel phase III pain relief product as the leading drug candidate and seeks to revolutionize the pain segment of the pharmaceutical market by developing a lucrative pipeline of analgesics without the classic opioid side effects. Charleston's new novel product line will address a large unmet need for patients being treated for moderate to severe pain with narcotic analgesics
by reducing or totally eliminating opioid induced nausea and vomiting (OINV)
while providing uninterrupted pain therapy. Charleston Laboratories' lead compound, CL-108, contains a commonly-used opioid analgesic with acetaminophen combined with a commonly-used low dose anti-emetic in a specialized tablet formulation and release technology, resulting in immediate-release of the anti-emetic and priming the CNS to prevent nausea and vomiting associated with the opioid.
